Omega-3 fatty acids (FAs), which include eicosapentaenoic acid (EPA) and docosahexaenoic acid, are found in fish oils and have long been investigated as components of therapy for various disease states. Population studies initially revealed the cardioprotective and anti-inflammatory effects of omega-3 FAs and EPA, with subsequent clinical studies supporting the therapeutic role of omega-3 FAs in cardiovascular and chronic inflammatory conditions. Prospective randomized placebo-controlled trials have also demonstrated the utility of omega-3 FA supplementation in malignancy and cancer cachexia. In recent years, in vitro and animal studies have elucidated some of the mechanistic explanations underlying the wide range of biological effects produced by omega-3 FAs and EPA, including their antiproliferative and anticachectic actions in malignancy. In this review, the authors discuss the recent progress made with omega-3 FAs, focusing on the advances in mechanistic understanding and the results of clinical trials.
Although Hugh Sinclair initially examined the relationship between dietary fatty acids and disease in the 1950s, 1 the pioneering work in the 1970s on the production of different thromboxane (TX) and prostaglandin (PG) species from various fatty acid (FA) precursors raised specific interest in the topic of omega-3 versus omega-6 Fas. [2] [3] [4] [5] The cardioprotective benefits of dietary omega-3 FAs were first reported by Dyerberg and Bang as they studied the rarity of death in Greenland Eskimos from cardiovascular disease. [6] [7] [8] Despite the prevalence of obesity and high dietary fat content, mortality from coronary heart disease (CHD) remained paradoxically low among the Greenland Inuits. [9] [10] [11] [12] It was noted that marine animals such as whales, seals, and fish that comprise the Eskimo diet contain a high amount of omega-3 FAs, in contrast to the high omega-6 FA content of vegetable oils in the Western diet. 13 Unlike the Danish control population, Greenland Eskimos demonstrated high blood levels of omega-3 FAs, specifically eicosapentaenoic acid (EPA), and extremely low levels of omega-6 FAs, namely, arachidonic acid (AA). 14 Subsequently, fatty fish consumption or omega-3 FA intake was established to be inversely proportional to mortality from CHD in a variety of populations. [15] [16] [17] [18] [19] [20] [21] In addition, omega-3 FAs and EPA have since been shown to have inhibitory effects in tumor growth, cancer cachexia, and a variety of inflammatory conditions. [22] [23] [24] [25] The distinction between omega-3 and omega-6 FAs begins with structural dissimilarities (Figure 1 ). In the designation of FA structure, the numerical notation indicates the number of carbon atoms followed by the number of double bonds and an omega designation (ω-or n-) referring to the position of the first double bond from the methyl terminus. Therefore, EPA (20:5 ω-3) refers to a 20-carbon polyunsaturated fatty acid (PUFA) containing 5 double bonds with the first double bond located at the third bond position from the methyl terminus, and AA (20:4 ω-6) designates a 20carbon PUFA containing 4 double bonds with the first located 6 positions away from the methyl terminus. These seemingly minor structural differences result in significant variations in biological properties. For instance, omega-3 FAs such as EPA and docosahexaenoic acid (DHA) have inhibitory effects on inflammation and tumorigenesis, but omega-6 FAs such as AA and linoleic acid have proinflammatory and tumor-growth-enhancing properties. [26] [27] [28] Although there is evidence that DHA and linolenic acid may significantly contribute to the salutary effects of omega-3 FAs, we will focus on the work done with EPA in this review.
EPA exerts its effects in part by inhibiting the AA lipid peroxidation pathway in 3 related ways and also by inhibiting other inflammatory or mitogenic signaling pathways ( Figure 2 ). First, EPA replaces AA in phospholipid membranes, reducing the amount of AA substrate for formation of biologically active leukotrienes of the 4-series and prostanoids of the 2series (such as prostacyclin/PGI 2 , PGE 2 , and TXA 2 ). Second, EPA competes with AA for lipoxygenase and cyclooxygenase (COX) enzymes, both the constitutive COX-1 isoform and, more important, the inducible COX-2 isoform, which is upregulated by proinflammatory signals. 29, 30 The structure of EPA forces it to bind COX-2 in a strained conformation that slows its enzymatic conversion rate and causes EPA to behave somewhat similarly to an irreversible selective COX-2 inhibitor. 31 Third, EPA itself is a substrate that is converted into leukotrienes of the 5-series and prostenoids of the 3-series, tipping the balance toward antiaggregation of platelets and vasodilatation with the production of active PGI 3 but biologically inactive TXA 3 . [32] [33] [34] EPA also alters other signal transduction pathways, which may better explain its potent anti-inflammatory and antiproliferative effects. 35 EPA inhibits the nuclear translocation of the transcription factor, nuclear factor kappa-B (NFκB), resulting in decreased production of proinflammatory cytokines such as interleukin-1 and tumor necrosis factor-α. [36] [37] [38] In addition, EPA reduces activator protein-1 (AP-1) transcription factor activity by inhibiting the mitogenactivated protein kinase (MAPK) pathway. 39 Early studies suggested that EPA was effective in reducing the levels of proinflammatory cytokines in chronic inflammatory conditions and ameliorating cancer-associated cachexia. Antiproliferative effects of EPA have also been demonstrated in several in vitro and animal models of malignancy. EPA inhibited the in vitro growth of many pancreatic cell lines, in part through cell cycle arrest and induction of apoptosis. 40 In addition, preincubation of a pancreatic cancer cell line in an omega-3 FA emulsion containing EPA inhibited malignant cell proliferation induced by epidermal growth factor. 41 In a rat model of nonmetastasizing fibrosarcoma, EPA supplementation reduced tumor volume, improved cachexia, and decreased expression of growth factors. 27, 42 Similar inhibitory effects of omega-3 FA supplementation on the growth and metastases of tumors were observed in nude mouse models of breast or prostate cancer. [43] [44] [45] [46] [47] The results of these animal studies were confirmed by clinical studies demonstrating the utility of omega-3 FA or EPA supplementation in human inflammatory diseases and malignancy. 23, [48] [49] [50] In this review, we will specifically focus on the progress made with EPA in these clinical conditions. Since EPA is an essential component of fish oil or omega-3 FA supplementation with comparable biological effects on its own, we will include in our discussion studies that used fish oil or omega-3 FA supplements containing EPA. 27, 28 
EPA Supplementation in Inflammatory Conditions
The process of atherosclerosis is considered by many to be an inflammatory condition, with atherogenesis being a reaction to endothelial injury that involves the infiltration of lipid-laden macrophages and atheromatous proliferation of monoclonal cells. Therefore, reduction of CHD-related mortality by omega-3 FAs may be explained by general anti-inflammatory effects of EPA in addition to the antiaggregatory actions of EPA on platelets. Fish oil supplementation inhibited the histologic progression of atherosclerosis in rhesus monkeys or swine that were fed an atherogenic diet. 51, 52 In a prospective clinical study, dietary salmon oil supplementation resulted in the incorporation of omega-3 FAs into platelet membranes, reduction of platelet aggregation in response to ADP, and prolongation of Figure 1 Representatives of the omega-6 and omega-3 fatty acid families. In fatty acid designation, the first number within parentheses refers to the number of total carbon atoms, the second refers to the number of double bonds, and the omega designation refers to the number of bonds between the first double bond and the methyl end. Members within each family can be interconverted by reactions that include desaturation and elongation, but it is not possible to transform members of one family into members of the other. Therefore, the majority of omega-6 fatty acids are derived from dietary vegetable oils, and omega-3 fatty acids are primarily derived from marine animal sources in the diet. Linoleic acid and -linolenic acid are considered to be essential dietary fatty acids, which are necessary for life but unable to be synthesized by the body. It is possible to synthesize eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) from -linolenic acid, but this is a slow and inefficient process. To effectively increase the body levels of EPA or DHA, they must be directly consumed.
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bleeding times. 53 Five-year mortality due to coronary artery disease (CAD) was reduced for consumers of fish, 54 and improvement of CAD as assessed by angiography was associated with reductions in blood levels of inflammatory cytokines and growth factors. 55, 56 However, many of these clinical studies were performed in patients with established CAD and varied in the form of EPA supplement used, producing mixed results ( Table 1) .
EPA supplementation has also shown benefits in the treatment of autoimmune and inflammatory diseases such as systemic lupus erythematosus (SLE), inflammatory bowel disease, rheumatoid arthritis, and psoriasis ( Table 2 ). 23 The severity of lupus nephritis was reduced by fish oil supplementation in murine models as well as in clinical trials. [57] [58] [59] Remission was improved and prolonged with EPA supplementation in patients with SLE. [60] [61] [62] It is interesting to note that premature atherosclerosis is a common complication of SLE, supporting a common inflammatory link between the 2 pathogenic processes, which are concomitantly improved by EPA treatment. 59, 63 In inflammatory bowel disease, fish oil treatment reduced disease index, joint pain, serum cholesterol, and EPA then competes with AA for cyclooxygenase (COX) and lipoxygenase (LOX) enzymes as EPA and AA are released from phospholipids by the membrane-bound phospholipase-A2 (PLA2) enzyme. EPA is converted to prostaglandins of the 3series and leukotrienes of the 5-series, which differ in biological properties from AA lipid peroxidation products. For instance, thromboxane A 2 (TXA 2 ) promotes platelet aggregation and vasoconstriction, which is opposed and balanced by the actions of prostaglandin I 2 (PGI 2 ); however, thromboxane A 3 (TXA 3 ) has little biological activity and tips the balance toward antiaggregation due to the effects of prostaglandin I 3 (PGI 3 ). Leukotrienes of the 5-series are also less biologically active than those of the 4series, which may explain the beneficial effects of EPA in asthma and other inflammatory conditions. In addition to its effects on the lipid peroxidation pathway, EPA inhibits the activation of NF B and decreases the formation of proinflammatory cytokines such as tumor necrosis factor-alpha (TNF-) and interleukin-6 (IL-6). Although the signaling intermediates have yet to be fully elucidated, EPA also inhibits the mitogen-activated protein kinase pathway (MAPK) and activator protein-1 (AP-1) translocation, responsible for mitogenesis and cell proliferation.
corticosteroid requirement in patients with Crohn's disease or ulcerative colitis. [64] [65] [66] [67] [68] [69] Enteric-coated fish oil capsules also decreased the frequency of relapse in patients with Crohn's disease. 70 For patients with rheumatoid arthritis, EPA improved clinical outcomes and reduced the need for nonsteroidal anti-inflammatory drugs in several double-blinded, placebo-controlled trials. [71] [72] [73] [74] [75] [76] [77] [78] Combined with a diet low in AA, fish oil supplementation decreased the number of tender and swollen joints in patients with rheumatoid arthritis. 79 In psoriasis, patients receiving an omega-3 FA lipid emulsion demonstrated improvements in psoriatic lesions in comparison to those receiving an omega-6 FA lipid emulsion. 80, 81 EPA may improve inflammatory diseases of the lung such as asthma and cystic fibrosis in addition to systemic inflammatory conditions. 3 5 , 8 2 Dietary supplementation with EPA in patients with atopic asthma inhibited leukotriene formation. 83 Omega-3 FAs are believed to induce beneficial effects in cystic fibrosis by decreasing NFκB activation as well as inflammatory eicosanoid production. 84 Eight months of omega-3 FA supplementation improved clinical parameters in cystic fibrosis, including pulmonary function tests and days of antibiotic therapy required. 85 EPA treatment has also shown promise for improving outcomes in acute pancreatitis, sepsis, and noninfectious systemic inflammatory conditions (Table 3) . In a rat model of acute pancreatitis, fish oil supplementation via total parenteral nutrition (TPN) improved respiratory and renal function. 86 In clinical trials, omega-3 FAs reduced hypertriglyceridemia, which is a risk factor for acute pancreatitis. [87] [88] [89] Parenteral supplementation with omega-3 FAs also showed clinical benefits in patients with overwhelming systemic inflammatory conditions, such as sepsis and acute respiratory distress syndrome. 90 Oral EPA supplementation also reduced the inflammatory complications of bone marrow transplantation, which were primarily related to the systemic inflammatory response syndrome. 91 Since the tumor-bearing state often resembles systemic inflammatory disease in terms of cytokine activity, immune dysfunction, and malnutrition, it is logical that EPA would have beneficial effects in a variety of inflammatory conditions as well as in malignancies.
EPA Supplementation in Cachexia and Malignancy

Cancer Cachexia
Systemic changes secondary to the presence of malignancy produce the syndrome called cancer cachexia, which is defined by an imbalance toward catabolism despite the adequate presence of nutrients. The cachexia syndrome is characterized by anorexia, anemia, and weight loss that most notably affects lean body mass. 92 The severe malnutrition and wasting caused by cachexia can result in up to 50% of deaths in patients with gastrointestinal (GI) cancers and 80% of those with advanced pancreatic cancer. 93 Cachexia compromises the patient's quality of life through degradation of skeletal muscles while comparatively preserving visceral proteins, and it eventually leads to death due to respiratory muscle atrophy. 94 The pathogenesis of cancer cachexia involves the production of proinflammatory cytokines and acute phase reactants along with the activation of proteolytic pathways, which are opposed by EPA. 26, 95 Weight-losing patients with malignancy demonstrate improvements in appetite, body weight, nutritional parameters, and clinical performance parameters with EPA supplementation (Table 4 ). EPAenhanced enteral formulas have shown benefits in clinical trials for cachectic patients with various general malignancies. 96 In advanced pancreatic cancer patients, the use of fish oil supplement containing EPA with enteral nutrition inhibited the acute phase response and helped normalize metabolic parameters, leading to reversal of weight loss and increase in lean body tissue. 92, [97] [98] [99] [100] Pancreatic cancer patients receiving EPA also experienced improvements in appetite and performance status. 101 Since the pathophysiology of cachexia involves an assortment of Topical omega-3 FAs improved lesions from baseline but showed no differences from placebo FA = fatty acid; RCT = randomized placebo-controlled study; SLE = systemic lupus erythematosus; IBD = inflammatory bowel disease; RA = rheumatoid arthritis; NSAIDs = nonsteroidal anti-inflammatory drugs; GLA = gamma-linolenic acid. proinflammatory cytokines and AA products, cancer cachexia may be viewed as a chronic inflammatory condition that benefits from EPA-supplemented nutrition.
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Perioperative EPA Supplementation
In clinical trials for a variety of GI malignancies, perioperative omega-3 FA supplementation decreased the length of hospital stay, reduced postoperative complications, improved immunologic parameters, and increased constitutive protein levels while decreasing serum levels of proinflammatory cytokines ( Table 5 ). Omega-3 FAs also reduced the in-cidence and severity of postoperative infections in addition to improving gut function in patients with gastric or pancreatic cancer. 1 0 2 , 1 0 3 The timing of perioperative omega-3 FA supplementation in relation to surgery did not appear to make a difference, whether supplementation occurred preoperatively, postoperatively, or both. [103] [104] [105] [106] [107] Studies have shown that perioperative enteral administration of omega-3 FAs is cost-effective in supporting malnourished cancer patients and reducing postoperative complications. 96, 108 The beneficial effects of EPA on the immune response and reduction of postoperative infections in malignancy have promoted the idea of EPA as a component of perioperative immunonutrition. Omega-3 FAs are often used in conjunction with other immunonutrients such as arginine, glutamine, and RNA to maximize positive effects on the immune system and postoperative recovery. In a retrospective study, perioperative EPA supplementation was noted to additionally improve immunologic parameters in patients receiving postoperative chemoradiation therapy for esophageal cancer. 109 In support of this observation, a prospective randomized controlled trial demonstrated that patients receiving EPAsupplemented TPN experienced less stress-induced immunosuppression following thoracotomy for esophageal cancer resection. 110 Although the levels of proinflammatory cytokines were reduced in this study, EPA stimulated natural killer cell and lymphocyte activity. Therefore, the modulatory effects of EPA on the immune response must be more mechanistically complex than our current understanding since EPA treatment reduces postoperative infections but also helps normalize the inappropriately overactive immune response in autoimmune diseases.
Inhibition of Tumor Growth
In animal models of malignancy, EPA treatment has demonstrated success in reducing tumor growth and inducing cell cycle arrest in cancerous cells. 27, 28, [111] [112] [113] The antiproliferative actions of EPA are putatively due to the following mechanisms: induction of apoptosis by reduced bcl-2 expression, increased differentiation of cancer cells, decreased AP-1 and ras oncogene expression, reduction of COX-2 expression or availability, inhibition of NFκB activation, and decreased production of proinflammatory cytokines. 49, 114, 115 Some of these mechanisms may be linked by EPA-mediated inhibition of MAPK cascade signaling intermediates, which are involved in both the activation of the proinflammatory transcription factor NFκB and the onco-genic transcription factor AP-1. Omega-3 FAs inhibited the activation of AP-1, in part by reducing the phosphorylation of extracellular signal-regulated kinases 1 and 2 (ERK1/ERK2). [116] [117] [118] In a lipopolysaccharidestimulated murine macrophage model, omega-3 FA emulsion inhibited AP-1 activation and the phosphorylation of MAPK intermediates p44/42 and jun N-terminal kinase/stress-activated protein kinase. 39 In the same model, omega-3 FA emulsion also reduced the activation of NFκB by preventing inhibitory-κB (IκB) phosphorylation and dissociation, resulting in the decreased production of proinflammatory cytokines. 37, 119 There is also evidence that EPA may downregulate vascular endothelial growth factor ligands and receptors, thereby reducing the blood supply necessary for tumor growth. 42, 120 There have not been any clinical trials on the effects of EPA on the growth or metastases of unresectable human tumors, to the best of our knowledge. Unlike most animal tumor models, surgical resection is often used as a primary mode of therapy in human solid tumors, especially in GI cancers, and EPA is limited to serving as a component of nutritional supplementation or adjuvant therapy. However, omega-3 FAs have been used with success in reducing toxicity associated with stereotactic radiotherapy for brain metastasis in patients with various cancers. 121 EPA has also demonstrated the ability to sensitize rat astrocytoma cells to radiotherapy-induced cell death. 122 Although there is anecdotal evidence on the use of EPA as a component of adjuvant chemotherapy, there have been no reported clinical trials to date on this application. Based on in vitro and animal studies, EPA may be beneficial in producing cytotoxic or antiproliferative effects on tumor growth, reducing metastases, and reducing inflammation-associated collateral cell death in normal tissues. Clinical trials to test the use of EPA as a component of adjuvant chemoradiotherapy are warranted.
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Forms of EPA Supplementation
One of the significant challenges in providing EPA supplementation is that delivery is often limited by low purity and the requirement of high doses. 123 Although pharmaceutical-grade EPA and fish oil capsules are commercially available, these products are also sold as over-the-counter dietary supplements of unknown purity. Since lipids such as EPA are rapidly oxidized, effective supplements must also contain antioxidants such as vitamin E and be stored in nonoxidizing conditions. Low purity, rapid oxidation, and the limited rate of gut absorption contribute to the requirement of high doses. Side effects of enteral EPA supplementation are GI in nature and include abdominal discomfort, diarrhea, belching, and fish-scented halitosis; many of these side effects can be circumvented by the use of enteric-coated capsules or parenteral administration. Since omega-3 FAs are also available from natural sources, it is possible to incorporate EPA into the diet for patients who are able to tolerate oral intake in the form of fatty fish such as salmon, mackerel, herring, anchovy, or trout. However, natural dietary intake is difficult to monitor or quantify and should not be included in dosing calculations for cancer patients.
As omega-6 FAs such as AA directly compete with EPA for incorporation into cell membranes, the ratio of omega-3 to omega-6 FAs comprising intake is also an important consideration. In patients with rheumatoid arthritis, fish oil supplement showed clinical benefits only in those with a background omega-6 FA intake of less than 10 g/d. 75 Basic parenteral nutrition usually delivers omega-3 FA:omega-6 FA at a low ratio of 1:7, whereas ratios of 2:1 to 5:1 have been associated with beneficial effects in colorectal or breast cancer, decreased mortality in cardiovascular disease, reduction of inflammation in rheumatoid arthritis, and improvements in asthma. 124 To achieve this level, doses of 1 to 5 g/d of omega-3 FAs have been used effectively in clinical studies 125, 126 ; minimal doses of 1 g/d EPA for at least 1 week were necessary to produce an observable therapeutic effect in cancer studies. In clinical trials testing maximum tolerated doses, fish oil capsules were successfully administered at extremely high doses of 18 g/d (or 0.3 g/kg/d) for at least 1 month in patients with cancer cachexia, as the limiting toxicity for higher doses was GI discomfort or diarrhea. 123, 127 No such side effects were reported by patients receiving enteric-coated EPA capsules, in contrast to 50% of those receiving uncoated capsules. 128 Since EPA delivers a concentrated source of calories in addition to therapeutic effects, administering the highest tolerable and cost-effective dose in cancer cachexia may be justified.
Results have been variable in basic science and clinical studies involving EPA or omega-3 FAs, which may be in part due to the variations in dose and type of supplement in addition to the length of treatment period and study design. There may also be significant differences in outcome between enteral and parenteral EPA administration, especially in GI malignancies associated with abnormal gut function. Clinical studies have shown that parenteral omega-3 FA administration results in more significant and rapid improvements compared to oral supplementation in psoriasis. 80 Intravenous omega-3 lipid emulsions have recently become commercially available in a sterile pharmaceuticalgrade form that can be delivered parenterally and can be studied in comparison to intravenous omega-6 FA emulsion controls.
Another concern with EPA supplementation has been the possibility of bleeding complications since the decrease in platelet aggregation observed in Greenland Eskimos was accompanied by a mild bruising tendency. 53, 129 Although omega-3 FAs decrease the incidence of CHD and ischemic strokes, [130] [131] [132] they are believed to increase the risk for hemorrhagic strokes. 9, 133 However, clinical studies have demonstrated that EPA does not increase bleeding complications in patients undergoing major surgery or coronary angioplasty and in dialysis patients with end-stage renal disease, although measured bleeding times were modestly increased. [134] [135] [136] [137] [138] Yet it may be prudent to use EPA supplementation with caution in patients with a history of familial bleeding disorders such as von Willebrand's disease; hemophilia A, B, or C; Bernard-Soulier's disease; or Glanzmann's thrombasthenia. fects beyond the AA lipid peroxidation pathway. Clinical studies have confirmed the therapeutic potential of omega-3 FAs in inflammatory conditions and malignancy. Further research is necessary to elucidate essential signaling intermediates and the role of omega-3 FAs in adjuvant cancer therapy. Additional studies are also needed to clarify the best forms and routes of omega-3 FA administration.
